Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659350 | 0.90 | MAPT (0.44) | ESR2MAPTNR1H2L3MBTL1GPR119 | |
| SCHEMBL3705234 | 0.89 | MAPT (0.48) | ESR2PARP1TNKS2PARP2MAPT | |
| SCHEMBL17373227 | 0.87 | NR1H2 (0.40) | ESR2PARP1TNKS2PARP2MAPT | |
| SCHEMBL2795751 | 0.83 | PARP1 (0.51) | ESR2PARP1TNKS2PARP2MAPT | |
| SCHEMBL2799009 | 0.81 | MAPT (0.48) | ESR2PARP1TNKS2PARP2MAPT | |
| SCHEMBL12662820 | 0.80 | BAZ2B (0.43) | MAPTMAPK1 | |
| SCHEMBL2482118 | 0.79 | PARP1 (0.45) | ESR2PARP1TNKS2PARP2MAPT | |
| SCHEMBL6423555 | 0.78 | HRH4 (0.39) | GRM5POLB | |
| SCHEMBL11515494 | 0.76 | BAZ2B (0.43) | F12POLB | |
| SCHEMBL2505488 | 0.76 | PARP1 (0.42) | ESR2PARP1TNKS2PARP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3883576-B1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2024186626-A1 | AZA-BICYCLIC STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| WO-2009158394-A1 | DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | DHFR, DHPS, DCK | ESR2 2680/4885PARP1 1659/4885TNKS2 337/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | ESR2 2104/4885PARP1 1163/4885TNKS2 1735/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | ESR2 2737/4885PARP1 3298/4885TNKS2 1326/4885 |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | DHFR, DHPS, DCK | ESR2 2680/4885PARP1 1659/4885TNKS2 337/4885 |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2B, ADORA2A, ADORA3 | ESR2 640/4885PARP1 719/4885TNKS2 592/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | ESR2 893/4885PARP1 192/4885TNKS2 924/4885 |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA1 | ESR2 918/4885PARP1 828/4885TNKS2 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.